A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

V Nygaard, AH Ree, VJ Dagenborg… - Cancer Research …, 2023 - AACR
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …
被引用次数：1 相关文章

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

V Nygaard, AH Ree, VJ Dagenborg… - Cancer Research …, 2023 - duo.uio.no
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

V Nygaard, AH Ree, VJ Dagenborg… - Cancer research …, 2023 - pubmed.ncbi.nlm.nih.gov
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …
[PDF] aacrjournals.org

[PDF][PDF] A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver …

V Nygaard, AH Ree, VJ Dagenborg… - Cancer Research …, 2023 - AACR
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …

A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases

V Nygaard, A Ree, V Dagenborg… - Cancer Research …, 2023 - europepmc.org
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …
[HTML] nih.gov

[HTML][HTML] A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver …

V Nygaard, AH Ree, VJ Dagenborg… - Cancer Research …, 2023 - ncbi.nlm.nih.gov
Disease recurrence and drug resistance are major challenges in the clinical management of
patients with colorectal cancer liver metastases (CLM), and because tumors are generally …